Return to study ST001943 main page
MB Sample ID: SA184284
| Local Sample ID: | Healthy24h_8 |
| Subject ID: | SU002035 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 53 ± 15 |
| Weight Or Weight Range: | 116 ± 25 |
| Gender: | Male and female |
| Human Inclusion Criteria: | (i) body mass index (BMI)>35kg/m2 plus GFR 30–60ml/min and proteinuria >1 g/24h or GFR>60ml/min and proteinuria >2.5 g/24h despite receiving maximally tolerated doses of renin-angiotensin-aldosterone system (RAAS) blocker and (ii) BMI>40kg/m2 with a GFR>30ml/min and proteinuria >0.5 g/24h despite receiving maximally tolerated doses of RAAS blocker. For the renal function criterion, eGFR was used. The follow-up time was 24 months. |
| Human Exclusion Criteria: | 1) Patients who had participated or were participating in another clinical trial or had taken an experimental drug in the last 28 days. 2) Patients with renal transplantation and/or chronic replacement therapy (hemodialysis and/or peritoneal dialysis). 3) Subjects with poorly controlled blood pressure (SBP > 170 mmHg or DBP > 110 mmHg). 4) Patients with a history of cardiovascular events in the past six months. 5) Patients treated with immunosuppressants. 6) Subjects with a history of renovascular disease, autoimmune diseases, cancer, drug use, or obstructive uropathy. 6) Patients who did not sign the informed consent. 7) Patients who were pregnant or lactating. eGFR was used to establish the renal function criteria. Patients were monitored for 24 months. |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN003187 |
|---|---|
| Analysis type | MS |
| Chromatography type | None (Direct infusion) |
| Chromatography system | none |
| Column | none |
| MS Type | EI |
| MS instrument type | CE-TOF-MS |
| MS instrument name | Agilent 6224 TOF |
| Ion Mode | POSITIVE |
| Units | Area |
Chromatography:
| Chromatography ID: | CH002355 |
| Chromatography Summary: | Analysis were performed in a capillary electrophoresis (CE) system coupled to a TOF-MS analyser (TOF: time-of-flight) purchased from Agilent Technologies (CE: 7100, MS: 6224). In coupling process, steath liquid was supplied by an ISO pump (Agilent 1200) to increase the volatility and compensate the volume for MS through an electrospray source. A fused silica capillary was used to perform metabolite separation (100 cm total length x 50 μm i.d. x 360 μm o.d., provided by Agilent Technologies). Capillary was conditioned with water, BGE and NaOH. Before analysis, capillary was rinsed for 5 min at 950 mbar with BGE and was applied a voltage of 30kV for 10 s to displace BGE ions. After conditioning, sample was loaded applying 50 mbar for 50 s, then, BGE was applied at 100 mbar for 10 s. In the capillary was applied a pressure of 25 mbar and a voltage of 30 kV to achieve metabolite separation. A positively charged spray is formed by a flow of 0.6 mL min−1 (1:100 split) when separated compounds leave the capillary from the auxiliary liquid system with a nebulization pressure of 10 psig with nitrogen and a capillary voltage of 3500 V. A hot nitrogen flow of 10 mL min−1 at 200 °C was applied to dry the spray. |
| Instrument Name: | none |
| Column Name: | none |
| Chromatography Type: | None (Direct infusion) |
